This year, a large number of drugs will be transferred out of medical insurance

[Pharmaceutical Network Market Analysis] Earlier, the National Medical Insurance Administration stipulated that the provincial medical insurance department should speed up the digestion of the original self-supplemented varieties to ensure that all digestion work is completed before June 30, 2022
.

At present, the time has come to February, and there are only about 4 months left before the above stipulated time
.

From the current point of view, the transfer or digestion of medical insurance catalogues in various provinces across the country is gradually and orderly, and the transfer of local medical insurance is also becoming more and more intensive.
Many provinces and cities such as Anhui, Guizhou, Zhejiang, Jiangsu, etc.
have released related file, and arrange specific varieties to call out time
.

Among them, it is worth mentioning that Qinghai, Yunnan and other provinces and cities have also made it clear that there will be a batch of drugs that will no longer be reimbursed this year
.

For example, the "Announcement on Chongqing Municipality's Gradual Digestion of the List of Locally Supplemented Medical Insurance Class B Drugs" issued by the Chongqing Municipal Medical Insurance Bureau stipulates that the real estate drugs with purchased data and those produced and sold by local pharmaceutical companies and whose sales ratio exceeds 20% in Chongqing Other non-property drugs are included in the final year of digestion
.

The 89 medicines included in the third year of digestion will stop being reimbursed by medical insurance from July 1, 2022
.

The Yunnan Provincial Medical Insurance Bureau issued a notice on the "Digestion and Adjustment Plan for Drugs Beyond the Scope of the National Medical Insurance Drug Catalog in Yunnan Province", stating that in order to strictly implement the "2019 National Drug Catalog", from 24:00 on June 30, 2020, the "2019 version" will be synchronously implemented.
The medicines listed in the National Drug Catalogue, the medicines that exceed the dosage forms paid by the national medical insurance, the decoction pieces of traditional Chinese medicines that meet the state's clear non-payment, and the national key monitoring drugs will not be reimbursed by medical insurance
.

According to the proportion and progress of digestive medicines in Yunnan Province, there are 162 digestive medicines in the third year, accounting for 19.
355% of the digestive medicines, and medical insurance reimbursement ends at 24:00 on June 30, 2022
.

In addition, the Zhejiang Provincial Medical Insurance Bureau issued a notice on the public solicitation of the "Notice on Transferring Some Drugs from Zhejiang Province's Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (Draft for Comment)", which also clearly mentioned that from January 2022 From January 1, 118 drugs have been transferred out of the Zhejiang Provincial Medical Insurance Catalogue
.

 　　From the above comprehensive point of view, the transfer time is roughly the same in various places.
In 2022, a large number of drugs will be intensively transferred out of local medical insurance
.

It is worth noting that drugs that are included in the medical insurance list can achieve rapid volume growth, and sales may increase significantly in the short term, and sales may also increase exponentially
.

 　　But at the same time, the sales of drugs that have been removed from the catalog will face a significant drop in sales
.

This is undoubtedly a big challenge for some pharmaceutical companies
.

In this regard, industry analysts believe that with the continuous updating of the national medical insurance catalogue and the implementation of the drug digestion and adjustment plans within the scope of the medical insurance catalogues in various provinces, the accelerated withdrawal of a large number of drugs from medical insurance and the reshuffle of the pharmaceutical industry are destined to become the general trend
.

 　　In the future, pharmaceutical representatives and pharmaceutical companies will usher in huge opportunities and challenges
.

In this context, for pharmaceutical representatives, they should learn to be active and flexible, and pharmaceutical companies should increase investment in research and development of innovative drugs to continuously enhance their competitiveness
.

  　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.